Chronic Urticaria – Unmet Need – Unmet Need – Chronic Urticaria (US/EU)
Treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and used off-label (e.g., DMARDs, immunosuppressants, tricyclic antidepressants). However, several of these drug classes can have serious side effects, and many patients still struggle to control their symptoms. Novartis / Roche’s Xolair is the first and only US FDA-approved biologic for CSU, with Sanofi / Regeneron’s Dupixent used off-label and under regulatory review in both regions. Clinical trials of additional biological and oral targeted therapies are under way, but with only one biologic approved for chronic urticaria, the factors that can positively differentiate emerging drugs from current therapies remain unknown, and many unmet needs in this space remain unfulfilled.
Questions answered
- With few targeted therapies available, what unmet needs remain in the treatment of chronic urticaria?
- Which clinical trial endpoints and nonclinical attributes are key influencers of dermatologists’ and allergists’ prescribing decisions, and which have limited impact? What are areas of hidden opportunity?
- How does Xolair perform on key treatment drivers and goals? How does its performance compare with that of frequently prescribed conventional therapies, including immunosuppressants and antihistamines?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists and allergists for a hypothetical new chronic urticaria drug?
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 30 U.S. allergists, 30 U.S. dermatologists, 15 European allergists, and 15 European dermatologists conducted in January 2025.
60 U.S. and 30 European dermatologists and allergists
Key drugs covered: Xolair, Dupixent, remibrutinib, antihistamines, montelukast, immunosuppressants
